Skip to main content

Table 1 General characteristics at baseline and clinical findings during follow-up of the study population (n = 54)

From: Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study

Parameter

 

Age (years), median [IQR]

60 [58–63]

Sex, no. (%)

 M/F

46 (85)/8 (15)

BMI, kg/m2, median [IQR]

27 [25.5–28.1]

Blood pressure (mmHg), median [IQR]

 Systolic

130 [120–131.2]

 Diastolic

80 [70–80]

Hypertension, no. (%)

15 (28)

Smoke, no. (%)

43 (80)

Cholesterol (mg/dL), median [IQR]

 Total

172 [149.5–189]

 HDL

42.5 [35–51]

 LDL

103 [68–128]

Triglycerides (mg/dL), median [IQR]

127 [105.2–151.5]

Glycemia (mg/dL), median [IQR]

 Baseline

87 [80–90.2]

 2 h

109 [93–126.7]

Glycated hemoglobin (%), median [IQR]

5.2 [5.1–5.5]

Insulin (µU/mL), median [IQR]

3.8 [3–6]

HOMA IR, median [IQR]

0.78 [0.59–1.31]

Creatinine (mg/dL), median [IQR]

1 [0.87–1.1]

Hemoglobin (mg/dL), median [IQR]

14.3 [13.3–15.2]

Adiponectin (µg/mL), median [IQR]

11 [9.7–13.2]

Adiponectin, no. (%)

 Pathologic

13 (24)

Resistin (ng/mL), median [IQR]

7 [4–9]

Resistin, no. (%)

 Pathologic

8 (15)

 TNF-alpha (ng/mL), median [IQR]

8.5 [7–11]

TNF-alpha, no. (%)

 Pathologic

6 (11)

Site of stenosis at first PCI, no. (%)

 IVA

25 (46)

 CX

10 (19)

 DX

19 (35)

Follow-up duration (months), median [IQR]

29.5 [14.7–34]

Re-PCI, no. (%)

4 (7)

Time re-PCI, median [IQR]

8.5 [4–15.75]

Site of re-PCI, no. (%)

 IVA

3 (75)

 CX

0 (−)

 DX

1 (25)

New PCI, no. (%)

5 (9)

Time new PCI, median [IQR]

29 [IQR 12–33.5]

Site of new-PCI, no. (%)

 IVA

2 (40)

 CX

1 (20)

 DX

2 (40)

Death, no. (%)

 Cardiovascular/other causes

− /1 (2)